Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin With Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma
Cancer - United States
doi 10.1002/cncr.30026
Full Text
Open PDFAbstract
Available in full text
Date
May 18, 2016
Authors
Publisher
Wiley